Isoniazid (H) is one of the most important first-line medicines for the treatment of active
tuberculosis (TB) and latent TB infection (LTBI), with high bactericidal activity and a good safety profile. The emergence of TB strains resistant to isoniazid threaten to reduce the effectiveness of TB treatment....
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...
The global priorities for tuberculosis (TB) care and control are to improve case-detection and to detect cases earlier, including cases of smear-negative disease which are often associated with coinfection with the human immunodeficiency virus (HIV) and young age, and to enhance the capacity to diagnose ...
Tuberculosis (TB) contacts are people who have close contact with patients with infectious TB.
As they are at high risk for infection (and in line with the Stop TB strategy), TB contacts should
be investigated systematically and actively for TB infection and disease. Such interventions
are called ‘tube...
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increasingly occur in resource-constrained settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centres) will need t...
